Table 1

Clinical characteristics of cohort

Gleason grade groupT-stageNumber of patientsAge
(mean±SD)
PSA
(ng/mL)
Neoadjuvant ADTRelapse
21c459.3±7.96.1±1.60/4
2a270.5±3.57.7±4.60/2
2b270.0±1.48.8±1.90/2
Total864.8±8.07.1±2.50/8 (0%)
31c563.0±4.521.6±32.81/51
2b365.3±4.212.1±6.80/3
2c170.011.31/1
3a167.011.20/11
3b157.080.01/1
Total1164.1±4.722.4±28.83/11 (27%)
41c176.027.71/1
2a170.06.10/1
Total273.0±4.216.9±15.31/2 (50%)
52a166.06.40/1
2b173.07.21/1
3b167.010.31/11
Total368.7±3.88.0±2.12/3 (67%)
2465.6±6.215.1±20.76/24 (25%)3/24 (12.5%)
  • ADT, androgen deprivation therapy.